Results 161 to 170 of about 5,328 (181)
Some of the next articles are maybe not open access.
Entrectinib: First Global Approval
Drugs, 2019Entrectinib (Rozlytrek®) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment
Zaina T, Al-Salama, Susan J, Keam
openaire +2 more sources